PureTech Health has named new Chief Medical Officer to see all clinical operations across its pipeline and will focus on pushing chances that have most potential for patients, the Boston-based company said Thursday.
The new CMO is Atul Pande, M.D, who has more than two decades of experience in drug development. He is the former Senior Vice President, Head of Neuroscience, and Senior Advisor, Pharmaceutical R&D at GlaxoSmithKline. His experience includes drug development, registration, launch and lifecycle management in the areas of anxiety, depression, epilepsy, neuropathic pain, schizophrenia, traumatic brain injury, and Alzheimer’s and Parkinson’s diseases.
Dr. Pande commented: “I am proud and delighted to join this stellar team and hope to be instrumental in enabling the launch of some of the truly innovative medicines in the PureTech Health pipeline. Having been involved in clinical research and development for more than twenty years, I believe that the PureTech Health approach – which starts with ground-breaking science and signals of human efficacy and stresses safety – has important advantages.”
Daphne Zohar, Chief Executive Officer of PureTech Health, says: “Atul is a seasoned drug development veteran who will help to shepherd our advancing pipeline through mid- and late-stage clinical trials while ensuring that synergies are leveraged across our platforms.”